Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Within- and between-group changes in metabolic syndrome variables over 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

  Baseline Week 12 Within-group mean change over 12 weeksa Between-group mean change over 12 weeksb
Outcome n Mean ± SD n Mean ± SD Mean (95% CI) Mean (95% CI) P
Waist circumference (cm)
 EXE 13 106.8 ± 14.2 13 105.6 ± 14.4 −1.2 (−3.3, − 1.0) −3.7 (−6.6, − 0.8) 0.01
 NoEXE 19 97.9 ± 10.1 19 99.6 ± 12.4 2.0 (0.2, 3.7)   
Systolic blood pressure (mm Hg)
 EXE 13 122.2 ± 14.2 13 122.4 ± 15.3 −1.4 (− 8.5, 5.7) −5.1 (− 15.5, 5.3) 0.32
 NoEXE 19 128.8 ± 13.0 19 129.8 ± 14.0 2.1 (−3.8, 7.9)   
Diastolic blood pressure (mm Hg)
 EXE 13 76.9 ± 9.2 13 75.4 ± 8.9 −1.9 (−6.3, 2.5) − 0.5 (− 6.8, 5.8) 0.87
 NoEXE 19 79 ± 5.1 19 79.0 ± 8.6 0.3 (−3.3, 4.0)   
HDL-C (mg/dL)
 EXE 13 46.5 ± 12.2 12 49.0 ± 19.0 3.8 (−1.9, 9.6) 6.1 (− 1.6, 13.8) 0.11
 NoEXE 19 61.3 ± 16.3 19 61.5 ± 18.4 − 0.3 (−4.8, 4.1)   
Triglycerides (mg/dL)
 EXE 13 152.9 ± 65.4 12 148.7 ± 42.4 −3.7 (−31.9, 24.4) −6.7 (− 46.7, 33.2) 0.73
 NoEXE 19 131.63 ± 63.7 19 130.2 ± 79.5 −3.6 (−25.8, 18.6)   
Glucose (mg/dL)
 EXE 13 106.1 ± 33.0 13 103.7 ± 18.1 −4.0 (−9.8, 1.8) − 4.7 (− 13.2, 3.8) 0.27
 NoEXE 19 104.5 ± 20.3 19 104.7 ± 20.4 −0.4 (−5.2, 4.4)   
Insulin (mU/L)
 EXE 13 7.9 ± 7.6 12 5.5 ± 2.7 −1.3 (−5.6, 2.9) −2.0 (−8.1, 4.0) 0.50
 NoEXE 19 4.9 ± 4.7 19 6.6 ± 9.2 0.9 (−2.4, 4.3)   
HOMA-IR
 EXE 13 2.6 ± 4.2 12 1.4 ± 0.7 −0.6 (− 1.9, 0.6) −0.7 (−2.5, 1.0) 0.39
 NoEXE 19 1.3 ± 1.5 19 1.8 ± 2.6 −0.01(−1.0, 1.0)   
  1. Data presented as mean ± standard deviation. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH); HDL-C; high-density lipoprotein cholesterol; HOMA-IR, homeostatic model of assessment of insulin resistance
  2. aEXE relative to NoEXE adjusted for baseline values
  3. bEXE relative to NoEXE adjusted for baseline values, protein supplementation, body mass index and number of comorbidities